Effects of SARS-CoV-2 strain variation on virus neutralisation titres: therapeutic use of convalescent plasma

Effects of SARS-CoV-2 strain variation on virus neutralisation titres: therapeutic use of convalescent plasma

We compared neutralising antibody titres of convalescent samples collected before and after the emergence of novel strains of SARS-CoV-2, against the wild-type virus (WT), Alpha (B.1.1.7) and Beta (B.1.351) variants. Plasma collected in 2020 before emergence of variants showed reduced titres against...

Full description

Bibliographic Details
Main Authors:	Nguyen, D, Xiao, J, Simmonds, P, Lamikanra, A, Odon, V, Ratcliff, J, Townsend, A, Roberts, DJ, Harvala, H
Format:	Journal article
Language:	English
Published:	Oxford University Press 2021

Similar Items

Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma
by: Verbrugghe, C, et al.
Published: (2024)

Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma
by: Samantha K Davis, et al.
Published: (2022-01-01)

Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS‐CoV‐2
by: Valk, SJ, et al.
Published: (2021)

Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization
by: Harvala, H, et al.
Published: (2022)

Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels
by: Harvala, H, et al.
Published: (2020)

Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay
by: Emma M. Bentley, et al.
Published: (2021-08-01)

Comparison of SARS‐CoV‐2 neutralizing antibody testing of convalescent plasma donations in the Netherlands and England: A pilot study
by: Heli Harvala, et al.
Published: (2021-12-01)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
by: Deborah Cromer, PhD, et al.
Published: (2022-01-01)

Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients
by: Ngai Sze Wong, et al.
Published: (2022-05-01)

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
by: Alexander P. Underwood, et al.
Published: (2021-09-01)

SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
by: Lumley, SF, et al.
Published: (2020)

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
by: Desmarets, M, et al.
Published: (2023)

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents
by: Naomi S. Coombes, et al.
Published: (2023-02-01)

Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.
by: Helen R Savage, et al.
Published: (2021-07-01)

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
by: Eric Toussirot, et al.
Published: (2023-04-01)

Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients
by: Diego Cantoni, et al.
Published: (2022-05-01)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
by: Alexander Wilhelm, et al.
Published: (2022-08-01)

Convalescent plasma as a therapeutic agent for SARS-CoV, MERS-CoV and SARS-CoV-2: A scoping review
by: Abeba Haile Mariamenatu, et al.
Published: (2021-01-01)

Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020
by: Thompson, CP, et al.
Published: (2020)

Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
by: Izani, Wani Husna Mohd
Published: (2023)

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
by: Hirsch, C, et al.
Published: (2021)

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
by: Maurice Steenhuis, et al.
Published: (2021-01-01)

Neutralizing antibody titres in SARS-CoV-2 infections
by: Eric H. Y. Lau, et al.
Published: (2021-01-01)

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
by: Kreuzberger, N, et al.
Published: (2021)

Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
by: Piechotta, V, et al.
Published: (2021)

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
by: Mohamed Moubarak, et al.
Published: (2021-07-01)

Clinical efficacy and safety of convalescent plasma therapy for patients with SARS-CoV-2 infection
by: D. V. Lavrenchuk, et al.
Published: (2022-04-01)

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
by: Kenji Maeda, et al.
Published: (2021-03-01)

The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
by: Shinta Oktya Wardhani, et al.
Published: (2021-07-01)

Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.
by: Diego S Ojeda, et al.
Published: (2021-01-01)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
by: George W. Carnell, et al.
Published: (2023-02-01)

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
by: Andrea Picchianti-Diamanti, et al.
Published: (2023-11-01)

Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays
by: Inesa Hyseni, et al.
Published: (2020-09-01)

Therapeutic use of convalescent plasma in patients with COVID-19
by: Leobaldo Prieto Jiménez, et al.
Published: (2020-11-01)

SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma
by: Jesse D. Deere, et al.
Published: (2021-12-01)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
by: Lorenza Bellusci, et al.
Published: (2023-04-01)

Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
by: M. Carmen Martin, et al.
Published: (2022-01-01)

Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects
by: Latha Dulipsingh, et al.
Published: (2023-06-01)

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
by: Huo, J, et al.
Published: (2021)

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
by: Natalie Yan-Lin Pang, et al.
Published: (2021-08-01)